X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
Clinical trial NCT04415320 · UNKNOWN
Trial details
- NCT number
- NCT04415320
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-21
- Primary completion
- 2020-12-01
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.